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Abstract
Purpose The optimal components for rehabilitation in patients with incurable cancer are unclear. However, principles of exercise and
nutrition-based interventions used in cancer cachexia may be applied usefully to this population of cancer patients. This systematic
review examines current evidence for rehabilitation combining exercise and nutritional support in patients with incurable cancer.
Methods MEDLINE, EMBASE and Cochrane databases were searched. Eligible studies included patients with incurable cancer
and rehabilitation programmes combining exercise and nutritional interventions. Studies of cancer survivors, curative treatments,
reviews, case note reviews, protocols and abstracts were excluded. Grading of Recommendations Assessment, Development and
Evaluation (GRADE) criteria were applied to patient-important outcomes.
Results Of the 2424 search results, 67 abstracts were reviewed and 24 full texts examined. Eight studies (n = 685) were included
comprising two randomised control trials, three prospective, one exploratory and two secondary analyses. All examined multi-
modal outpatient programmes. GRADE analysis revealed moderate evidence (B) for improvements in depression and physical
endurance, low-quality evidence (C) for quality of life and fatigue and very low–quality evidence (D) for overall function and
nutritional status.
Conclusion There are limited data for multi-modal rehabilitation programmes combining exercise and nutritional interventions in
patients with incurable cancer. However, studies to date report improvements in multiple domains, most notably physical
endurance and depression scores. This supports the concept that multi-modal rehabilitation incorporating principles of cachexia
management may be appropriate for the wider group of patients with incurable cancer. Further, high-quality studies are needed to
define the optimal approach and outcome measures.
Keywords Rehabilitation . Palliativemedicine . Exercise . Nutrition therapy
Introduction
Patients with cancer are living longer than ever before; indeed,
in many cases, cancer is now considered a chronic disease [1,
2]. While this is clearly a positive development, the conse-
quences of patients living longer with cancer are wide and
varied. With longer survival comes an increase in morbidity
and increased healthcare costs with associated socio-
economic implications [3]. There is a need to take a pro-
active approach to this evolving situation and to optimise the
overall condition of patients living with cancer, including
those with incurable disease [4]. Rehabilitation may be one
such way of optimising the function and overall quality of life
(QoL) of this patient population.
Rehabilitation is a concept widely embraced by Western
medicine for the management of acute and chronic illness
and has recently been advocated for patients with incurable
cancer, including those receiving treatment with palliative in-
tent [5–7]. Although ‘rehabilitation’ for patients with incur-
able cancer may seem paradoxical, there is a plausible argu-
ment that patients whose overall condition is compromised
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have the most to gain from appropriately tailored intervention
[7]. In patients with advanced disease, rehabilitation aims at
improving and/or maintaining function where the effects of
the illness or its treatment threaten to cause decline, or to ease
the transition toward dependency when functional deteriora-
tion is inevitable. Promoting patients’ own interests and social
engagement and optimising functional independence are fun-
damental [7]. It is acknowledged widely that rehabilitation in
patients with incurable cancer should be multi-modal and tai-
lored [5, 7, 8] yet, there is a lack of evidence as to the most
efficacious components of a rehabilitation programme for this
patient population [2].
The emerging principles of optimising physical and nutri-
tional function in patients with cancer cachexia would seem
appropriate to be applied to a broader rehabilitation concept in
all patients with cancer. Cachexia is defined as ‘an ongoing
loss of skeletal muscle mass (with or without fat mass) that
cannot be fully reversed by conventional nutritional support
and leads to protein breakdown, and resultant loss of muscle
mass and functional decline’ [9]. It is common in solid tu-
mours, which account for over 50% of cancer deaths world-
wide and affects over half of all patients with advanced cancer
[10]. Cachexia adversely affects function and QoL and is an
independent predictor of poorer treatment response, side-
effect profiles and shorter survival [11–13]. The high preva-
lence of cachexia in patients with incurable cancer alone
means that any rehabilitation intervention for this group
should consider key components of cachexia.
Cachexia is characterised by involuntary weight loss and a
negative energy balance created by reduced oral intake, alter-
ations in body metabolism and inflammation [10]. Dietary
interventions alone are not effective in reversing cancer-
related cachexia, [11, 14] due to metabolic alterations includ-
ing elevated energy expenditure, excess catabolism and in-
flammation [10], which together prevent muscle anabolism
(the ‘anabolic blockade’) [11]. Exercise stimulates skeletal
muscle anabolism, leading to increased muscle mass and
strength; however, supra-normal protein intake is required to
achieve the same post-prandial anabolic effects in cachectic
patients [11]. Introducing exercise without nutritional support
in this group of patients may exacerbate the negative energy
balance. Work to date has demonstrated that cancer cachexia
is best targeted through a pro-active, multi-modal intervention
that aims to improve lean mass (muscle), physical function
and overall QoL [11, 15]. This pro-active and multi-modal
approach advocated for cancer cachexia has the potential to
be adopted usefully as a rehabilitation approach for patients
with incurable cancer.
Patients with incurable cancer frequently suffer from symp-
tom clusters (SCs), where two or more interrelated symptoms
present together, independent of other SCs: raising the
possibly of a common aetiology or mechanism [16].
Examples include the fatigue/anorexia-cachexia and the
fatigue/neuro-psychological clusters, which have been clini-
cally and statistically defined. Proinflammatory cytokines
may play a role in the aetiology of SCs [17], and thus, the
multi-modal rehabilitation approach advocated for cancer ca-
chexia may also play a useful role in the management of SCs.
Exercise is feasible in patients with incurable cancer and
has multiple beneficial effects on physical well-being, fatigue
and depression, all impacting on overall QoL [2, 18]. Based
on work to date, there is a strong rationale that exercise and
nutrition in combination should be key constituents of any
rehabilitation programme for patients with cancer; however,
the details of any such programme remain to be elucidated [5].
The aim of this systematic review is therefore to examine
current evidence for combined exercise and nutritional reha-
bilitation interventions in patients with incurable cancer.
Materials and methods
Ethical approval was not required for this systematic review.
The following databases were searched electronically:
MEDLINE, EMBASE and the Cochrane Library. The time
frame was 1990 to current. The keywords and search strategy
are outlined in Appendix 1. The literature search was per-
formed between February 26, 2018 and March 5, 2018. A
consort diagram (Fig. 1) was performed as per PRISMA
guidelines.
Eligibility criteria
Studies met the following inclusion criteria: patients with in-
curable cancer (defined as metastatic cancer [histological, cy-
tological or radiological evidence] or locally advanced cancer
being treated with palliative intent); rehabilitation
programmes including both exercise and nutritional compo-
nents; all methodologies; studies in humans; and English
language.
Studies were excluded if they met any of the following
criteria: studies of cancer survivors or carers of cancer pa-
tients; unimodal rehabilitation interventions; reviews; proto-
cols; case reports; retrospective case note reviews; conference
abstracts; and rehabilitation/prehabilitation for cancers man-
aged with curative intent.
Appraisal process
Titles were reviewed by CH then relevant abstracts screened
by CH and BL. Abstracts deemed relevant or requiring clari-
fication were reviewed at full text. Full texts were screened by
CH and BL and thematic analysis applied by JC and CH.
Estimates of effect extracted from studies included change
scores (pre-post measurements), effect sizes and P values.
Values were synthesised according to patient-important
Support Care Cancer
outcomes (see below) as well as outcomes of methodological
interest for future study design: feasibility, dropout rates, pre-
dictors of completion and cost-effectiveness.
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) analyses were undertaken by CH
and JC. Due to the complexity and to improve inter-rater reli-
ability, a checklist was developed [Supplementary material-on
request] based on the GRADE handbook and a validated
checklist for meta-analyses [19–21]. This was applied to indi-
vidual studies then to the body of evidence for patient-
important outcomes, which were decided a priori between
authors and ranked in order of importance. Where GRADE
discrepancies existed, these were discussed among the authors
and a consensus reached.
Results
Figure 1 shows the literature review process. The following
numbers of articles were retrieved from each database: 781
(MEDLINE), 1625 (EMBASE) and 18 (Cochrane Database
of Systematic Reviews).
A summary of the included studies is detailed in Table 1.
Eight studies were eligible enrolling a total of 685 participants.
Studies included two randomised control trials (RCTs) [22,
23], three prospective studies [24–26], two secondary
analyses of quasi-experimental data [1, 27] and one explorato-
ry study [28]. All interventions were outpatient-based rehabil-
itation programmes: seven in hospitals and one hospice-based.
Three studies examined the 8 to 12-week McGill Cancer
Nutrition Rehabilitation Programme (CNRP) [24–26], and
three studies examined the 8-week-Ottawa Palliative
Rehabilitation Programme (PRP) [1, 27]. Two studies exam-
ined novel rehabilitation programmes in the UK [23] and
Switzerland [22]. All programmes were interdisciplinary and
were individually tailored. Seven studies included core com-
ponents combining dietary modification/supplementation and
exercise [1, 22, 24–28]. The remaining study included dietary
and physiotherapy interventions as an optional (non-core) el-
ement dependent on patient goals: it was not possible to as-
certain numbers of participants receiving input from both
these specialists [23].
Studies and patient-important outcomes and were evaluat-
ed using the GRADE approach. Consensus was reached on
the quality of evidence for each patient-important outcome,
presented in Tables 2 and 3.
Feasibility and adverse events
Three studies (n = 300) commented on feasibility of the reha-
bilitation programmes or constituents of their interventions.
Patients attended a mean of 67% of bi-weekly exercise
Literature Search
Titles Screened (n=2424)
Excluded at Title
(n=2357)
Abstracts screened (n=67)
Excluded at Abstract (n=43)
• Reviews (17)
• Carer/ Cancer Survivors (8)
• Curave Intent (11)
• Protocol/ Abstract (2)
• Case Reports (2)
• Comment (1)
• Other (2)
Full texts screened (n=24)
Excluded at Full Text (n=16)
• Protocol (1)
• FT not available (Abstract) (1)
• Lack of nutrional intervenon (4)
• Curave intent (6)
• Lack of exercise intervenon (1)
• Retrospecve Case Note Review (3)
Full texts Included (n= 8)
Fig. 1 Consort diagram to show
the literature search process
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training classes over 3 months, and all patients managed at
least half of the ONS after each training session in one RCT
[22]. Similarly, for a 10–12-week CNRP, patients attended
82% of prescribed exercise sessions [26]. No adverse effects
were reported, but this was only mentioned in one study [22].
In the same trial, 3-month dropout rates due to death or with-
drawal were lower in the intervention group compared to the
control group: 4% vs. 24%, indicating feasibility. Over 90% of
patients reported the CNRP as important to them; however,
introducing this programme in a busy cancer centre was la-
bour-intensive, requiring a nurse, administrative and financial
support to be viable [25].
Dropout rates and predictors of programme
completion
Completion rates from CNRP/PRP programmes ranged from
42 to 70% [24, 26]. Dropout rates due to disease progression/
death accounted for between 49 and 61% [27, 28]. Other
reasons included geographical inaccessibility (39%) [24] or
unknown/personal reasons (37%) [28]. Schedules of medical
appointments made it hard to adhere to the CNRP, and at
times, the amount of information to take in could be over-
whelming [25]. Predictors of programme completion included
lower baseline CRP levels [24, 26], lower ECOG performance
Table 2 Summary of findings: modified due to study types. Patients or population: patients with incurable cancer. Settings: outpatient. Intervention:
multi-modal rehabilitation programmes comprising exercise and nutritional elements. Comparison: where available-standard care
Patient- important
outcomes
Studies N = total participants*
(breakdown per
outcome measure)
Quality of the
body of evidence
(GRADE)
Comments
Quality of life 3 [22, 23, 26] N = 214
129 (ESAS)
41 (EQ-VAS)
44 (EORTC C30)
Low (C) Two moderate quality studies with conflicting results, one
low-quality study showing improvement, studies have
limitations and inconsistencies in outcome variables.
Overall function 2 [25, 28] N = 81
56 (ECOG PS)
25 (KPS)
Very low (D) Two studies with low and very low-quality examined changes
in functional status scores, one finding significant and one
non-significant improvements. Sparse data with limitations.
Fatigue 4 [22, 24, 26, 28] N = 203
22 (BFI)
137 (MDFI)
44 (EORTC QLQ-C30)
Low (C) Two low, one very low-quality studies with limitations
showing significant improvements in fatigue in spite of
sparse data, and one high-quality (underpowered) study
showing non-significant improvements in intervention
group compared to control
Physical
endurance/-
strength
6 [22, 24–28] N = 342
6MWT (342)
HGS (64 within two of
the above studies)
Moderate (B) Six studies with quality overall low quality, with limitations:
variable consistency in significance levels but overall
magnitude of effect seen was improvement in spite of low
statistical power of studies: GRADE of evidence increased
(+2)
Depression 6 [1, 23, 24, 26–28] N = 371
211 (ESAS)
124 (HADS)
36 (SCNS-LF59)
Moderate (B) Overall low-quality studies with limitations but GRADE of
evidence increased (+2) due to studies all showing
consistent significant improvements in
depression/psychological subscales.
Nutrition/weight 5 [24, 26, 28] N = 285
107 (PG-SGA)
178 (weight)
Very low (D) Five studies of overall low quality with serious limitations and
indirectness (variable interventions). Two low-quality/very
low–quality studies showed improved PG-SGA scores but
the highest quality RCTshowed only significant increases in
protein intake. Evidence not strong enough to be upgraded.
*Total participants include numbers actually analysed within studies for each outcome as opposed to Table 1 showing ‘N’ as numbers enrolled into each
trial
Table 3 GRADE Definifions
GRADE Definition (from [20])
High (A) We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate (B) We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different
Low (C) Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low (D) We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
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status and better nutritional status [26]. Glare et al. [25] cited a
baseline 6-min walk test (6MWT) > 420 m, (i.e. better endur-
ance) as a predictor of programme completion. Although
within this study programme completers demonstrated im-
provements in multiple domains, high dropout rates (> 50%)
meant that earlier identification of the population who would
best respond was recommended.
Physical endurance, strength and overall function
Studies used multiple outcome measures; however, the 6MWT
was frequently cited as a marker of endurance and mean dis-
tances improved in six studies (n = 342). Two studies reported
performance status (ECOG/KPS) as primary endpoints (n = 81).
Feldstain and Chasen [27, 28] reported significant in-
creases in mean 6MWT distance (t(79) = − 3.91, P = < 0.001
[27] and d = 0.80, i.e.moderate-to-large effect size, P < 0.001
[28]) after the PRP. Studies utilising the CNRP quoted im-
provements in mean 6MWT distances between 41 m (95%
CI 29–52 m: effect size 0.7, P not reported [26]) and 58 m
[24] (non-significant, median 6MWT increase: P = 0.01).
Glare and Uster [22, 25] reported non-significant increases
in 6MWT (n = 25, median 441 m (186–675) to 570 m (range
not reported) [25], data presented graphically [22]) and other
physical parameters, though both studies were underpowered.
Chasen [28] reported an improvement in ECOG PS (P <
0.001, t = 6.43, d = 0.90) from mean 1.8 (± 0.7) to 1.29 (±
0.46) for patients completing the PRP, and Glare [25] reported
non-significant improvements in median KPS score (n = 25)
from 70% (score ≥ 50%:100%) to 80% (score ≥ 50%:100%)
in programme completers.
Fatigue, weakness and insomnia
Four studies described changes in fatigue (n = 211) using the
Brief Fatigue Inventory (BFI) [24], the Multidimensional
Fatigue Inventory (MDFI) [26, 28] and the European
Organisation for Research and Treatment of Cancer
(EORTC QLQ-C30) symptom scales [22].
Chasen [24] described improvements in BFI usual fatigue
(5.0 (1–10)–3.0 (1–9); P = 0.03) and fatigue now (5.0 (0–10)–
3.0 (0–10); P = 0.05). Furthermore, in 2013, using the MDFI,
reductions in general and physical fatigue (d = 0.61 and 0.55,
both P < 0.001) were reported [28]. Gagnon reported strong
improvements in MDFI activity and physical fatigue (mean 4.6
[95%CI 3.6–5.6] to 3.7 [95%CI 2.6–4.7] respectively, bothP <
0.001, effect size 0.8–1.1), moderate reductions in general fa-
tigue (mean change 2.8 [95%CI 1.8–3.8],P < 0.0001, effect size
0.7) and small but significant improvements in motivation and
mental fatigue (mean change 1.6 [95% CI 0.8–2.5], P = 0.0004
and 1.7 [95% CI 0.8–2.6] P = 0.0005: effect size both 0.4).
Reductions were seen in weakness (mean change 1.5 [95% CI
1.1–1.8], P < 0.0001, effect size 0.7) as well as reductions in
sleepiness and insomnia (mean change 1.1 [95% CI 0.6–1.6],
P < 0.0001 and mean change 1.0 [95% CI 0.5–1.4], P = 0.0001
effect size both 0.4) [26].
Effects on depression and quality of life
Six studies included endpoints examining depression (n = 371)
using the Edmonton Symptom Assessment Scale (ESAS) [24,
26, 28], the Hospital Anxiety and Depression Scale (HADs) [1,
27] and the psychological subscale of the Supportive Care
Needs Survey Long Form (SCNS-LF59) [23]. Studies fre-
quently mentioned QoL but only three studies reported a QoL
outcome using questions from the ESAS [26], EORTC QLQ-
C30 [22] and EQ-5D/EQ-VAS questionnaires [23].
Chasen reported improvements in (ESAS) nervousness and
depression (4.5 (0–10)–1.5 (0–5); P = 0.02 and (3.0 (0–9)–2.0
(0–7); P = 0.04 respectively) in 2010 [24] and depression
scores for those completing the PRP in 2013 (P = 0.005,
d = 0.37) [28]. Similarly, Gagnon [26] reported reductions in
(ESAS) depression scores (mean change 1.4 (95%CI 1.1–1.8)
P < 0.0001, effect size 0.7) as well as reduced (DT) distress
(mean change 1.4 (95% CI 0.9–1.9) P < 0.0001, effect size
0.5), improved (CT) coping (mean change 1.8 (95% CI 1.2–
2.4) P < 0.0001, effect size 0.7) and (ESAS) QoL (mean
change 1.0 (95% CI 0.6–1.3) P < 0.0001 effect size 0.5) after
the CNRP. One RCT demonstrated reduced unmet psycholog-
ical support needs on the psychological subscale of the SCNS
compared with controls (adjusted difference − 16.8 points
(95% CI − 28.34 to − 5.3) P = 0.006) and improvements in
(EQ-5D) self-reported health state (12.8, (95% CI 3.2–22.4)
P = 0.01) [23]. Conversely, the other RCT [22] showed no
difference global QoL. There was a non-significant trend to-
ward improvement; however, this trial was curtailed due to poor
recruitment and lacked power. Feldstain [27] described in-
creased self-efficacy (27.86 (SD = 6.16) to 31.23 units (SD =
5.77), P < 0.001) and reduced depression scores (7.14 (SD =
3.91) to 5.95 units (SD = 3.51), P = 0.002) after the PRP.
Changes in ‘self-efficacy’ (the perception that one can influence
life events/quality of functioning) accounted for the greatest
change (11%) in depression scores. In a subsequent study [1],
depression score improvements were maintained 3 months
post-PRP (mean difference T1–T3 = 2.21, SE 0.78, P = 0.007).
Nutritional status
Two studies measured weight as an outcome [22, 26], two
used the Patient-Generated Subjective Global Assessment
(PG-SGA) [24, 28] and one used a combination of both
[25]. Comparison between studies is hampered by lack of
detail on nutritional interventions, heterogeneity of subjects
and varied outcome measures. Nutritional counselling, dietary
advice and oral nutritional supplements (ONS) are mentioned
by most. Details of dietary interventions varied: 72% saw the
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physician, physiotherapist and dietitian, with 25% seeing the
physician and dietitian only in one [25]; 60–70% saw the
dietitian in another [1]; and in another, 94.7% received dietary
counselling, with 80.2% receiving ONS [26]. One RCT en-
sured patients received > 1.2 g protein/kg/day and encouraged
protein dense ONS (18–20 g in 125–200 mL) after exercise.
Significant improvements in protein intake (P = 0.01), but no
significant differences in energy intake or nutritional status
were seen between arms: indeed, weight increased in both
[22]. Patients undergoing nutritional interventions within mul-
tidisciplinary programmes maintained (77% within 2 kg) [26]
or increased their weight [22], although longitudinal data is
lacking. Increases in protein intake were not maintained
3 months post-intervention, dropping below baseline in both
groups, more so in the control group [22].
PG-SGA score improvements (median baseline 12.0 (2–24),
to 9.0 (1–18) at completion P = 0.05) were reported following
the CNRP [24] and also post-PRP (baseline mean (± SD) 8.15
(± 5.29) to 5.98 (± 4.14), t = 3.49, P = 0.001, d = 0.46) [28].
There was a higher mean PG-SGA score (89% ≥ 9 versus 70%
≥ 9) in dropouts of than those who returned for their 2-month
CNRP follow-up [25].
Cost-effectiveness
One RCT (n = 41) examined the cost-effectiveness of a 3-
month, complex hospice-based rehabilitation programme plus
usual care versus usual care alone [23]. The intervention was
associated with greater total costs (mean difference £955, 95%
CI £82–£1975) and greater QoL (mean difference 0.05
QALYs, 95% CI 0.000–0.112) resulting in an incremental
cost-effectiveness ratio (ICER) of £19,391 per quality-
adjusted life year (QALY) gained. The cost per QALY was
only calculated over the 3-month (intervention) period and
was close to the £20,000 threshold often used for incorpora-
tion of an intervention into the UK National Health Service.
The authors postulated that if the benefits of the programme
were maintained for 1 year, the ICER would decrease to ap-
proximately £4400 making the projection cost-effective in
92.7% of simulations at a threshold of £20,000 per QALY.
Discussion
There are few data available for multi-modal rehabilitation
programmes incorporating exercise and nutritional interven-
tions for patients with incurable cancer. However, of those
outcomes important to patients, many showed improvements
following the interventions described. Factors associated with
programme completion are higher baseline nutritional or func-
tional status and lower levels of inflammation. Of the studies
analysed, methodological quality was frequently limited by
study design and statistical power. Heterogeneity of study
design (including interventions and outcome measures) meant
meta-analysis was not appropriate.
In patients with incurable cancer, the highest quality of
evidence pertains to improvements in depression and physical
endurance following multi-modal rehabilitation programmes
including exercise and nutritional support. Depression is one
of the commonest mental health problems in patients with
advanced cancer [29]. Six studies showed improvements in
depression scores, using outcomes including the Hospital
Anxiety and Depression Scale (HADs). This scale, however,
does not differentiate clinical depression from sub-threshold
symptomatology, which is a limitation to its use in this patient
population [27].
A high level of evidence exists for exercise in rehabilitation
trials [2, 30], and this review suggests that the combination of
exercise and nutritional support also improves physical endur-
ance in patients with incurable cancer. Evidence for change in
overall function remains very low due to serious limitations in
the evidence (Table 2). Plausibly however, improvements in
physical endurance may impact on overall function via reduc-
tions in dependency.
Evidence for improved fatigue remains low. This finding is
in keepingwith the lack of interventions for fatigue in advanced
incurable disease. Rehabilitation studies in patients with cancer
are at risk of selection bias as patients recruited may be more
motivated, acknowledged by Uster [22]. Three studies mea-
sured QoL, but overall evidence for improvement remained
low. Cancer negatively affects QoL bymanymodalities; hence,
the necessity of a multi-modal approach in this patient group.
Results for nutritional parameters were variable, and it was
difficult to make comparisons, resulting in a very low rating
of evidence. Weight is a key feature of cachexia and (as an
outcome) is meaningful to both patients and clinicians [31],
but does not take into account body composition. PG-SGA
scores reflect changes in weight but also symptoms so may
not reflect alterations in nutritional status alone. Furthermore,
patients with incurable cancer are more likely to be at a ‘refrac-
tory’ stage of cachexia that is poorly responsive to treatment;
therefore, this level of evidence is unsurprising [9]. A further
confounding factor is that of contamination, whereby the con-
trol group mimics the intervention. Both groups gained weight
and improved hand grip strength within Uster’s RCT, which
may have contributed to a lack of statistical significance [22].
Cancer rehabilitation trials are frequently limited by design
and sample size and high attrition rates are common [32].
Recruitment issues were encountered in both RCTs; one cut
short due to poor recruitment [22], the other recruiting just
17% of expected patients. In this RCT, 189 eligible patients
were not approached, and interviews with recruiting clinicians
revealed reasons including discomfort with the trial design,
lack of confidence discussing prognosis and anxieties about
delivering the intervention at a hospice [23]. Other barriers to
recruitment include difficulties identifying participants
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(complex inclusion criteria) and high refusal rates (competing
priorities, fear of randomisation to non-preferred arm, lack of
acceptable control). Healthcare professional gatekeeping is one
of the most significant barriers to recruitment [33]; however,
patients find symptom control trials beneficial irrespective of
whether they obtain improvements in their symptoms [34].
Some of the findings presented herein are worthy of com-
parison to other diseases. The importance of exercise and nu-
tritional intervention is acknowledged in models of rehabilita-
tion for non-malignant disease, where cachexia may be pres-
ent. Pulmonary rehabilitation (PR) has included exercise as a
cornerstone for many years. Research on muscle dysfunction
in patients with chronic obstructive pulmonary disease
(COPD) has shown that multi-modal interventions including
exercise and nutritional supplementation can have beneficial
effects on body weight, exercise tolerance, physical activity,
depression and survival [35, 36]. There is now a shift toward
earlier PR to improve exercise tolerance and physical activity
and to promote self-efficacy and behavioural change while
reducing exacerbations [36]. These observations provide fur-
ther grounds for optimism that exercise and nutrition-based
rehabilitation programmes in patients with incurable cancer
are viable.
It is clear from work to date that the principles employed
in the treatment of cancer cachexia may be useful in rehabil-
itation. Work is ongoing to define the best approach to target
cachexia at all stages of disease: including ‘prehabilitation’
for patients undergoing cancer surgery [37], and a phase 3
trial is underway of a multi-modal cachexia treatment
(exercise, nutrition plus anti-inflammatories) for patients un-
dergoing chemotherapy [31]. A feasibility trial of a multi-
modal rehabilitation programme combining exercise and nu-
tritional support for hospice outpatients with incurable cancer
is also in progress [38]. There is a growing body of evidence
for the use of new technologies in oncology trials such as
physical activity monitors, which provide an objective mea-
surement of patient activity in their usual environment [39].
There is now strong international consensus that cachexia is a
multi-modal problem which requires multi-modal treatment
[10, 11]. One of the challenges in cancer cachexia, however,
is that the optimal endpoints are not clear, and this appears
similar in cancer rehabilitation studies where consensus on
endpoints is not evident [40]. Potential outcomes are numer-
ous, though it is important that measures are validated and
clinically meaningful [30]. GRADE discourages the use of
‘surrogate outcomes’, which can result in downgrading of
evidence for indirectness [20]. The aforementioned difficul-
ties in comparing trials due to the clinical and methodological
heterogeneity of interventions and outcomes may be one rea-
son for the slow growth of evidence in this field. There are
inherent difficulties however, performing clinical trials in a
field where personalised care makes standardising interven-
tions challenging [30].
For patients with incurable cancer, concerns about nutri-
tion, loss of function and increased dependency are common-
place. Loss of independence can compromise a person’s sense
of dignity and fears of functional decline can surpass fears of
impending death [41]. As the population changes, with im-
provements in anti-cancer treatment and greater numbers of
patients treated under the umbrella of palliative care, there is
the need to enable patients to live their lives as fully as possi-
ble, while minimising social-care costs. This approach, incor-
porating rehabilitation, places living before dying and is at the
heart of palliative care [6].
Limitations
The search strategy may have precluded relevant articles
due to stringency of the search criteria. One such factor was
exclusion of studies reporting results for ‘cancer survivors’.
The definition of this term is very broad, encompassing pa-
tients from initial diagnosis to death, and may also include
family, friends or caregivers [42]. Application of the
GRADE criteria can be advantageous due to transparency of
judgements about quality; however, limitations of the system
(including its use for assessment of individual studies) are
acknowledged [43]. A further challenge with GRADE is the
complexity which can result in poor-to moderate inter-rater
agreement [44]. Our GRADE checklist was designed to im-
prove this and, though effective, it is not a validated tool. The
lack of randomised control trials (two studies) meant that
meta-analysis was not possible. However, the use of the ro-
bustly validated GRADE system of analysis [19–21] ensured
that conclusions drawn were as accurate as possible.
Conclusion
This review demonstrates that in spite of limited data, multi-
modal rehabilitation programmes incorporating exercise and
nutritional interventions improve many outcomes that are im-
portant to patients with incurable cancer, most notably those
relating to physical endurance and depression. This finding,
along with factors associated with programme completion,
lends further support to the argument that exercise and nutri-
tional intervention should form integral components of cancer
rehabilitation. Multi-modal treatments are evolving for cancer
cachexia, and these may be usefully adapted to cancer
rehabilitation.
There are multiple opportunities to improve patient well-
being throughout all phases of cancer care: from the point of
diagnosis, prior to treatment and at the advanced stages of
incurable disease [4, 8]. Modern palliative care should now
encompass rehabilitation [6] as well as forming an integral
and concurrent element of active cancer care [45].
Rehabilitation for patients with incurable cancer has the po-
tential to significantly improve functional status and QoL for
the ever-increasing numbers of patients ‘living with cancer’,
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with potentially large socio-economic benefits. Further, care-
fully designed high-quality trials are needed, but the current
shift toward a joint rehabilitative-palliative approach through-
out the cancer trajectory shines a light in the dark for cancer
patients of the future.
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Appendix. Search Strategy
All terms searched within ‘Title’. Limits: Human subjects,
English language, year 1990–current.
MEDLINE. Total 781
1. Rehabilitation + Cancer: (578)
2. Rehabilitation + Cancer + Exercise: (36)
3. Rehabilitation + Cancer + Nutrition: (3)
4. Rehabilitation + Cancer + Exercise + Nutrition: (0)
5. Exercise + Cancer + Nutrition: (21)
6. Palliative + Rehabilitation: (42)
7. Palliative + Exercise + Nutrition: (0)
8. Prehabilitation: (81)
9. Prehabilitation + Cancer: (18)
10. Prehabilitation + Cancer + Palliative: (0)
11. Prehabilitation + Palliative: (0)
12. Prehabilitation + Nutrition (2)
EMBASE. Total 1625
1. Rehabilitation + Cancer: (1168)
2. Rehabilitation + Cancer + Exercise: (65)
3. Rehabilitation + Cancer + Nutrition: (10)
4. Rehabilitation + Cancer + Exercise + Nutrition: (0)
5. Exercise + Cancer + Nutrition: (50)
6. Palliative + Rehabilitation: (96)
7. Palliative + Exercise + Nutrition: (3)
8. Prehabilitation: (180)
9. Prehabilitation + Cancer: (50)
10. Prehabilitation + Cancer + Palliative: (0)
11. Prehabilitation + Palliative: (0)
12. Prehabilitation + Nutrition (3)
Cochrane Library. Total 18
1. Rehabilitation + Cancer: (2)
2. Rehabilitation + Cancer + Exercise: (4)
3. Rehabilitation + Cancer + Nutrition: (0)
4. Rehabilitation + Cancer + Exercise + Nutrition: (0)
5. Exercise + Cancer + Nutrition: (1)
6. Palliative + Rehabilitation: (2)
7. Palliative + exercise + nutrition: (0)
8. Prehabilitation: (1)
9. Prehabilitation + Cancer: (8)
10. Prehabilitation + Cancer + Palliative: (0)
11. Prehabilitation + Palliative: (0)
12. Prehabilitation + nutrition: (0)
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